Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 28130491.
- Also identified by DOI 10.1136/thoraxjnl-2016-209568 and PMC identifier 5388565.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated associations of plasma lipoproteins with subclinical interstitial lung disease (ILD) by measuring high attenuation areas (HAA: lung voxels between -600 and -250 Hounsfield units) in 6700 adults and serum MMP-7 and SP-A in 1216 adults age 45-84 without clinical cardiovascular disease in Multi-Ethnic Study of Atherosclerosis. In cross-sectional analyses, each SD decrement in high density lipoprotein cholesterol (HDL-C) was associated with a 2.12% HAA increment (95% CI 1.44% to 2.79%), a 3.53% MMP-7 increment (95% CI 0.93% to 6.07%) and a 6.37% SP-A increment (95% CI 1.35% to 11.13%), independent of demographics, smoking and inflammatory biomarkers. These findings support a novel hypothesis that HDL-C might influence subclinical lung injury and extracellular matrix remodelling.
Medical subject headings
- Lipoproteins
- Lung Diseases, Interstitial
- Pulmonary Surfactant-Associated Protein A